Search PubMed⌕ Search

Biomedical subjects

W K Engel

Publications and source records attributed to W K Engel.

At least 361 records · Page 20Linked to original sources
PubMed1966

Protein abnormalities in neuromuscular diseases--Part 2.

Different protein abnormalities have been found in several neuromuscular diseases and in some instances seem to be disease-specific. They do not necessarily represent "primary" defects and to date have only seldom led to beneficial therapy. But at the very least, these protein abnormalities provide handles which one may grasp in attempting to devise ways of arresting, curing, and preventing neuromuscular diseases.

Amyloidosis↗
PubMedDate not supplied

Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.

Three patients with Hypokalemic Periodic Paralysis (HOPP)-associated progressive interattack muscle weakness, who became unresponsive or worsened by acetazolamide, responded favorably to dichlorophenamide, a more potent carbonic anhydrase inhibitor. Dichlorophenamide in single-blind placebo-controlled trials, considerably improved functional strength in two of the patients and had a moderate but definite effect in the third. Muscle groups graded 4/5 (MRC scale)returned to normal; very weak (0-3/5) atrophic muscles, improved to a minor degree. In one patient with acetazolamide-resistant paralytic attacks, dichlorophenamide also diminished the frequency and severity of the acute attacks. Dichlorophenamide had, in the present study, less effect than acetazolamide in reducing serum HCO3(-) and elevating Cl-. Its effectiveness may be related to the degree of sensitivity of certain HOPP patients to alterations of Cl- and/or HCO3(-) serum levels or to a different action of the drug unrelated to carbonic anhydrase inhibition or acidosis. Dichlorophenamide should be considered as an alternate to acetazolamide in the treatment of patients with HOPP-associated interattack muscle weakness who have become unresponsive or worsened by acetazolamide.

Adult↗